Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: A cohort from an integrated health care delivery system

Journal of Clinical Oncology

Volumn 32, Issue 20, 2014, Pages 2151-2158

  Fehrenbacher, Louis ^a   Capra, Angela M ^a   Quesenberry Jr , Charles P ^a   Fulton, Regan ^a   Shiraz, Parveen ^b   Habel, Laurel A ^a  

^a KAISER PERMANENTE   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; DISTANT RECURRENCE FREE INTERVAL; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INVASIVE RECURRENCE FREE INTERVAL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; SYSTEMIC THERAPY; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CALIFORNIA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84905859224     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.0858     Document Type: Article

References (24)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989 (Pubitemid 19147683)
3. Arnould L, Gelly M, Penault-Llorca F, et al: Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267, 2006 (Pubitemid 43151545)
4. Musolino A, Naldi N, Bortesi B, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796, 2008
5. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
7. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (A-CT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC to TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-16, 2006 (abstr 52)
8. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
9. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
10. Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
11. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952-4960, 2007 (Pubitemid 350220427)
12. Burstein HJ, Winer EP: Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 27:5671-5673, 2009
13. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
14. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
15. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
16. Fehrenbacher L, Habel L, Capra A, et al: Incidence and demographic and tumor characteristics of HER2-positive invasive breast cancer in a large, unselected population, 2000-2006. Cancer Res 69, 2009 (suppl 3; abstr 3058)
17. Vacek PM, Geller BM, Weaver DL, et al: Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999. Cancer 94:2160-2168, 2002 (Pubitemid 34411972)
18. Luke C, Nguyen AM, Priest K, et al: Female breast cancers are getting smaller, but sociodemographic differences remain. Aust N Z J Public Health 28:312-316, 2004 (Pubitemid 40125269)
19. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP System. J Clin Oncol 25:2127-2132, 2007 (Pubitemid 46972801)
20. Kaiser Permanente Division of Research: Member Health Survey. http://www.dor.kaiser.org/external/DORExternal/mhs/2008-ncal-report.aspx
21. Reference deleted
22. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
23. Albert JM, Gonzalez-Angulo AM, Guray M, et al: Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 77:1296-1302, 2010
24. Verschraegen C, Vinh-Hung V, Cserni G, et al: Modeling the effect of tumor size in early breast cancer. Ann Surg 241:309-318, 2005